Background: Methicillin-resistant Staphylococcus aureus (MRSA) represents a significant threat to global public health. This bacterium, initially emerging in hospitals shortly after the introduction of methicillin, has become widespread in both healthcare and community settings. Its resistance to methicillin, and subsequently many other beta-lactam antibiotics, severely limits treatment options and contributes to increased morbidity, mortality, and healthcare costs. MRSA infections manifest in a variety of ways, ranging from relatively minor skin and soft tissue infections (SSTIs) like boils and abscesses, to more serious invasive infections such as pneumonia, endocarditis, and sepsis. The acquisition of the mecA gene, carried on a mobile genetic element called the staphylococcal cassette chromosome mec (SCCmec), is the primary mechanism conferring methicillin resistance. This gene encodes penicillin-binding protein 2a (PBP2a), which has a low affinity for beta lactam antibiotics, enabling cell wall synthesis to continue even in their presence. Various SCCmec types exist, each with different genetic characteristics and associated with specific MRSA clones. The spread of MRSA is facilitated by its ability to colonize both nares and skin, allowing for transmission through direct contact, contaminated surfaces, and airborne particles. Effective infection control measures, including hand hygiene, appropriate disinfection protocols, and judicious antibiotic use, are crucial for limiting MRSA transmission. Ongoing research focuses on developing new antibiotics, alternative therapies such as bacteriophage therapy, and vaccines to combat this persistent and evolving pathogen. Understanding the epidemiology, resistance mechanisms, and virulence factors of MRSA is essential for developing effective strategies for prevention and treatment.